首页 > 最新文献

Psoriasis (Auckland, N.Z.)最新文献

英文 中文
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. 治疗中重度斑块型银屑病和银屑病关节炎的新治疗方案:评估比美珠单抗及其治疗潜力
Q1 DERMATOLOGY Pub Date : 2019-05-24 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S179283
Andrea Chiricozzi, Clara De Simone, Barbara Fossati, Ketty Peris

Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.

斑块型银屑病(PsO)是一种慢性炎症性皮肤病,可能与包括关节炎在内的几种合并症有关。对牛皮癣发病机制的认识不断增加,导致了新的靶向治疗干预措施的确定。其中,抗il - 17a和抗il - 17f抗体目前正在研究用于治疗PsO和/或银屑病关节炎(PsA)。Bimekizumab是其中一种药物,能够同时中和IL-17A和IL-17F细胞因子。在这篇综述中,我们包括了与这种非常有前途的药物相关的临床前和临床数据,该药物显示出与其他双特异性药物不同的特殊分子结构。
{"title":"Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.","authors":"Andrea Chiricozzi,&nbsp;Clara De Simone,&nbsp;Barbara Fossati,&nbsp;Ketty Peris","doi":"10.2147/PTT.S179283","DOIUrl":"https://doi.org/10.2147/PTT.S179283","url":null,"abstract":"<p><p>Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"9 ","pages":"29-35"},"PeriodicalIF":0.0,"publicationDate":"2019-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S179283","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37341565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India. 聚焦伊托珠单抗治疗银屑病-来自印度的最新观点。
Q1 DERMATOLOGY Pub Date : 2019-05-03 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S154073
Leelavathy Budamakuntla, H V Shree-Lakshmi, Akshi Bansal, Shankar Kumar Venkatarayaraju

Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords "anti-CD6", "psoriasis", "phase trials", "case series", and "case reports". The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis.

银屑病是一种慢性、衰弱、免疫介导的全身炎症性疾病,主要影响皮肤、指甲和关节。根据疾病的严重程度,有几种治疗方式可供选择。长期使用这些药物会产生不良反应和毒性。最近,针对CD6的人源化单克隆免疫球蛋白G1抗体itolizumab在中重度慢性斑块型银屑病患者中显示出明显的临床效果和安全性。使用关键词“抗CD6”、“银屑病”、“阶段试验”、“病例系列”和“病例报告”进行文献检索。收集了2017年9月之前在印度进行的关于伊托珠单抗治疗银屑病疗效的所有研究的数据。本文概述了这些已发表文章中获得的临床数据。伊托珠单抗具有免疫调节和抗炎作用。它是有效的,并提供了良好的缓解期,因此代表了一种新的生物制剂,可以添加到银屑病的治疗药物中。
{"title":"Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India.","authors":"Leelavathy Budamakuntla,&nbsp;H V Shree-Lakshmi,&nbsp;Akshi Bansal,&nbsp;Shankar Kumar Venkatarayaraju","doi":"10.2147/PTT.S154073","DOIUrl":"10.2147/PTT.S154073","url":null,"abstract":"<p><p>Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords \"anti-CD6\", \"psoriasis\", \"phase trials\", \"case series\", and \"case reports\". The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"9 ","pages":"19-27"},"PeriodicalIF":0.0,"publicationDate":"2019-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S154073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37264200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Increased dermal expression of chromatin-associated protein HMGB1 and concomitant T-cell expression of the DNA RAGE in patients with psoriasis vulgaris. 寻常型银屑病患者真皮层染色质相关蛋白 HMGB1 的表达增加,同时 T 细胞表达 DNA RAGE。
IF 5.2 Q1 DERMATOLOGY Pub Date : 2019-02-12 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S190507
Lisa Strohbuecker, Hans Koenen, Esther van Rijssen, Bram van Cranenbroek, Esther Fasse, Irma Joosten, Andreas Körber, Christoph Bergmann

Purpose: Psoriasis vulgaris (PV) is an autoimmune-related chronic inflammatory disease of the skin, with both vascular and metabolic effects. Aggravating factors have been identified that initiate and maintain inflammation, including expression of Th1-, Th17-, and Th22-cell derived cytokines. Recently, we showed that the evolutionarily ancient and highly conserved damage-associated molecular pattern molecule "high mobility group box 1 (HMGB1)" is significantly increased in the serum of PV patients with disease progression and is decreased under standard therapies.

Materials and methods: To better understand the role of HMGB1 in the pathogenesis of PV, we recruited 22 untreated psoriatic patients with either mild or severe disease, defined by the Psoriasis Area Severity Index. We assessed HMGB1 and receptor for advanced glycation end products (RAGE) expression in the skin by immunohistochemistry and analyzed the immune-phenotype of Treg and Th17 cells by flow cytometry.

Results: We found increased staining for HMGB1 in the dermis of psoriatic plaques in comparison to uninvolved skin of patients with PV. In addition, the major histocompatibility complex class III-encoded DNA and HMGB1 RAGE, induced by HMGB1, were highly expressed on psoriatic CD8+ T cells and CD4+ Treg. High expression of HMGB1 in the lesional skin was associated with even higher expression of its receptor, RAGE, on the cell surface of keratino-cytes in patients with severe PV.

Conclusion: The presence of HMGB1 and RAGE signaling may impact orchestration of chronic inflammation in PV which might have implications for Treg and Th17 cells.

目的:寻常型银屑病(PV)是一种与自身免疫相关的慢性皮肤炎症性疾病,对血管和新陈代谢均有影响。已发现启动和维持炎症的加重因素,包括 Th1、Th17 和 Th22 细胞衍生细胞因子的表达。最近,我们发现,进化古老且高度保守的损伤相关分子模式分子 "高迁移率基团框 1(HMGB1)"在疾病进展期的紫癜患者血清中显著增加,并在标准疗法下减少:为了更好地了解 HMGB1 在 PV 发病机制中的作用,我们招募了 22 名未经治疗的银屑病患者,他们的病情或轻或重(以银屑病面积严重程度指数为标准)。我们用免疫组化方法评估了皮肤中 HMGB1 和高级糖化终产物受体(RAGE)的表达,并用流式细胞术分析了 Treg 和 Th17 细胞的免疫表型:结果:我们发现银屑病斑块真皮层中的HMGB1染色比未受银屑病影响的皮肤要高。此外,由 HMGB1 诱导的主要组织相容性复合体 III 类编码 DNA 和 HMGB1 RAGE 在银屑病 CD8+ T 细胞和 CD4+ Treg 上高表达。在重度 PV 患者的皮损皮肤中,HMGB1 的高表达与其受体 RAGE 在角质细胞细胞表面的高表达有关:结论:HMGB1 和 RAGE 信号的存在可能会影响 PV 中慢性炎症的协调,这可能会对 Treg 和 Th17 细胞产生影响。
{"title":"Increased dermal expression of chromatin-associated protein HMGB1 and concomitant T-cell expression of the DNA RAGE in patients with psoriasis vulgaris.","authors":"Lisa Strohbuecker, Hans Koenen, Esther van Rijssen, Bram van Cranenbroek, Esther Fasse, Irma Joosten, Andreas Körber, Christoph Bergmann","doi":"10.2147/PTT.S190507","DOIUrl":"10.2147/PTT.S190507","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis vulgaris (PV) is an autoimmune-related chronic inflammatory disease of the skin, with both vascular and metabolic effects. Aggravating factors have been identified that initiate and maintain inflammation, including expression of Th1-, Th17-, and Th22-cell derived cytokines. Recently, we showed that the evolutionarily ancient and highly conserved damage-associated molecular pattern molecule \"high mobility group box 1 (HMGB1)\" is significantly increased in the serum of PV patients with disease progression and is decreased under standard therapies.</p><p><strong>Materials and methods: </strong>To better understand the role of HMGB1 in the pathogenesis of PV, we recruited 22 untreated psoriatic patients with either mild or severe disease, defined by the Psoriasis Area Severity Index. We assessed HMGB1 and receptor for advanced glycation end products (RAGE) expression in the skin by immunohistochemistry and analyzed the immune-phenotype of Treg and Th17 cells by flow cytometry.</p><p><strong>Results: </strong>We found increased staining for HMGB1 in the dermis of psoriatic plaques in comparison to uninvolved skin of patients with PV. In addition, the major histocompatibility complex class III-encoded DNA and HMGB1 RAGE, induced by HMGB1, were highly expressed on psoriatic CD8+ T cells and CD4+ Treg. High expression of HMGB1 in the lesional skin was associated with even higher expression of its receptor, RAGE, on the cell surface of keratino-cytes in patients with severe PV.</p><p><strong>Conclusion: </strong>The presence of HMGB1 and RAGE signaling may impact orchestration of chronic inflammation in PV which might have implications for Treg and Th17 cells.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"9 ","pages":"7-17"},"PeriodicalIF":5.2,"publicationDate":"2019-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/9d/ptt-9-007.PMC6385765.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37207171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Type 2 diabetes and psoriasis: links and risks. 2型糖尿病和牛皮癣:联系和风险。
Q1 DERMATOLOGY Pub Date : 2019-01-17 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S159163
Jesper Grønlund Holm, Simon Francis Thomsen
Psoriasis (PsO) is one of the most common chronic inflammatory skin diseases with a world prevalence of 2%–4%. The increasing knowledge of the mechanisms driving PsO has raised focus on existing links to metabolic syndrome and type 2 diabetes (T2D). We reviewed the existing literature of the prevalence and risk of T2D in patients with PsO. The studies reviewed were mainly large retrospective cohort and case–control studies, showing an increased prevalence of T2D in PsO patients compared to controls, particularly in late onset (type 2) PsO. T2D prevalence did not correlate to patient age or severity of PsO in the reviewed studies. Conclusively, T2D was found to be more prevalent in patients with PsO compared to the background population. Several mechanisms involved in lipid transportation seem to be upregulated in PsO patients. Physicians play a key role concerning information about known comorbidity and promotion of early prophylaxis in patients with PsO.
牛皮癣(PsO)是最常见的慢性炎症性皮肤病之一,全球患病率为2%-4%。随着对PsO机制的了解不断增加,人们开始关注其与代谢综合征和2型糖尿病(T2D)之间的联系。我们回顾了关于PsO患者T2D患病率和风险的现有文献。回顾的研究主要是大型回顾性队列研究和病例对照研究,显示与对照组相比,PsO患者中T2D患病率增加,特别是在晚发性(2型)PsO中。在回顾的研究中,T2D患病率与患者年龄或PsO严重程度无关。最后,与背景人群相比,发现PsO患者中T2D更为普遍。参与脂质转运的几个机制似乎在PsO患者中上调。医生在了解已知合并症和促进PsO患者早期预防方面发挥着关键作用。
{"title":"Type 2 diabetes and psoriasis: links and risks.","authors":"Jesper Grønlund Holm,&nbsp;Simon Francis Thomsen","doi":"10.2147/PTT.S159163","DOIUrl":"https://doi.org/10.2147/PTT.S159163","url":null,"abstract":"Psoriasis (PsO) is one of the most common chronic inflammatory skin diseases with a world prevalence of 2%–4%. The increasing knowledge of the mechanisms driving PsO has raised focus on existing links to metabolic syndrome and type 2 diabetes (T2D). We reviewed the existing literature of the prevalence and risk of T2D in patients with PsO. The studies reviewed were mainly large retrospective cohort and case–control studies, showing an increased prevalence of T2D in PsO patients compared to controls, particularly in late onset (type 2) PsO. T2D prevalence did not correlate to patient age or severity of PsO in the reviewed studies. Conclusively, T2D was found to be more prevalent in patients with PsO compared to the background population. Several mechanisms involved in lipid transportation seem to be upregulated in PsO patients. Physicians play a key role concerning information about known comorbidity and promotion of early prophylaxis in patients with PsO.","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"9 ","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2019-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S159163","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36911410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
Psoriasis and sexual dysfunction: links, risks, and management challenges. 银屑病与性功能障碍:联系、风险和管理挑战。
Q1 DERMATOLOGY Pub Date : 2018-12-10 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S159916
Gleison V Duarte, Humberto Calmon, Gabriela Radel, Maria de Fátima Paim de Oliveira

According to the WHO, sexual health is not merely the absence of disease. Sexual dysfunction may be present in 40.8% of psoriasis patients, furthermore, 68% prevalence was found in Brazilian women with psoriasis. The moderate prevalence of psoriatic lesions in the genital area (35%-42%) does not explain the alarming prevalence of sexual dysfunction. Other factors, such as anxiety, depression, and also psoriasis treatment may contribute to its development. Likewise, atherosclerosis of the pelvic vasculature is involved in the pathogenesis of erectile dysfunction. Risk factors for erectile dysfunction tend to be confused with the comorbidities seen in psoriasis patients. We also highlight that it may serve as a marker of cardiovascular risk.

世卫组织认为,性健康不仅仅是没有疾病。40.8% 的银屑病患者可能存在性功能障碍,此外,在巴西的女性银屑病患者中,性功能障碍的发病率高达 68%。生殖器部位银屑病皮损的中等发病率(35%-42%)并不能解释性功能障碍的惊人发病率。焦虑、抑郁和银屑病治疗等其他因素也可能导致性功能障碍的发生。同样,骨盆血管的动脉粥样硬化也与勃起功能障碍的发病机制有关。勃起功能障碍的风险因素往往与银屑病患者的合并症相混淆。我们还强调,它可作为心血管风险的标志。
{"title":"Psoriasis and sexual dysfunction: links, risks, and management challenges.","authors":"Gleison V Duarte, Humberto Calmon, Gabriela Radel, Maria de Fátima Paim de Oliveira","doi":"10.2147/PTT.S159916","DOIUrl":"10.2147/PTT.S159916","url":null,"abstract":"<p><p>According to the WHO, sexual health is not merely the absence of disease. Sexual dysfunction may be present in 40.8% of psoriasis patients, furthermore, 68% prevalence was found in Brazilian women with psoriasis. The moderate prevalence of psoriatic lesions in the genital area (35%-42%) does not explain the alarming prevalence of sexual dysfunction. Other factors, such as anxiety, depression, and also psoriasis treatment may contribute to its development. Likewise, atherosclerosis of the pelvic vasculature is involved in the pathogenesis of erectile dysfunction. Risk factors for erectile dysfunction tend to be confused with the comorbidities seen in psoriasis patients. We also highlight that it may serve as a marker of cardiovascular risk.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"8 ","pages":"93-99"},"PeriodicalIF":0.0,"publicationDate":"2018-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/fa/ptt-8-093.PMC6292237.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36804316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. 聚焦于瑞桑单抗及其治疗斑块型银屑病的潜力:迄今为止的证据。
Q1 DERMATOLOGY Pub Date : 2018-11-13 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S165943
Álvaro Machado, Tiago Torres

Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients' quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab), and most recently IL-17 inhibitors. Risankizumab is a monoclonal antibody which targets IL-23p19 without binding IL-12. This novel therapeutic approach is expected to have advantages over the recently approved anti-IL-17 agents, such as the avoidance of Candida infections and neutropenia. In addition, unlike ustekinumab, the selective inhibition of IL-23 may preserve IL-12-dependent functions such as protection against infections and tumor immune surveillance. Risankizumab showed an excellent efficacy when compared to placebo and ustekinumab, with higher Psoriasis Area Severity Index (PASI) 75, PASI 90, and PASI 100 rates, along with a convenient every 12-week maintenance dosing regimen. Overall, risankizumab was well tolerated and the most common adverse event was upper respiratory tract infection. In the near future, further data will be available not only in psoriasis but also in Crohn's disease and psoriatic arthritis fields. Head-to-head trials comparing risankizumab with other IL-23 inhibitors and with IL-17 inhibitors will be crucial to reveal the role of risankizumab in the treatment of psoriasis.

牛皮癣是一种常见的慢性免疫介导的皮肤病,具有全身性,严重影响患者的生活质量。多年来已经开发了几种高度特异性的治疗方法,如肿瘤坏死因子-α抑制剂,非选择性IL-23抑制剂(ustekinumab),以及最近的IL-17抑制剂。Risankizumab是一种靶向IL-23p19的单克隆抗体,不结合IL-12。这种新的治疗方法有望比最近批准的抗il -17药物具有优势,例如避免念珠菌感染和中性粒细胞减少症。此外,与ustekinumab不同,选择性抑制IL-23可能保留il -12依赖的功能,如抗感染保护和肿瘤免疫监视。与安慰剂和ustekinumab相比,Risankizumab显示出出色的疗效,具有更高的银屑病区域严重指数(PASI) 75, PASI 90和PASI 100率,以及方便的每12周维持给药方案。总体而言,利桑单抗耐受性良好,最常见的不良事件是上呼吸道感染。在不久的将来,进一步的数据将不仅在牛皮癣,而且在克罗恩病和银屑病关节炎领域。比较利桑单抗与其他IL-23抑制剂和IL-17抑制剂的头对头试验对于揭示利桑单抗在治疗牛皮癣中的作用至关重要。
{"title":"Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.","authors":"Álvaro Machado,&nbsp;Tiago Torres","doi":"10.2147/PTT.S165943","DOIUrl":"https://doi.org/10.2147/PTT.S165943","url":null,"abstract":"<p><p>Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients' quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab), and most recently IL-17 inhibitors. Risankizumab is a monoclonal antibody which targets IL-23p19 without binding IL-12. This novel therapeutic approach is expected to have advantages over the recently approved anti-IL-17 agents, such as the avoidance of <i>Candida</i> infections and neutropenia. In addition, unlike ustekinumab, the selective inhibition of IL-23 may preserve IL-12-dependent functions such as protection against infections and tumor immune surveillance. Risankizumab showed an excellent efficacy when compared to placebo and ustekinumab, with higher Psoriasis Area Severity Index (PASI) 75, PASI 90, and PASI 100 rates, along with a convenient every 12-week maintenance dosing regimen. Overall, risankizumab was well tolerated and the most common adverse event was upper respiratory tract infection. In the near future, further data will be available not only in psoriasis but also in Crohn's disease and psoriatic arthritis fields. Head-to-head trials comparing risankizumab with other IL-23 inhibitors and with IL-17 inhibitors will be crucial to reveal the role of risankizumab in the treatment of psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"8 ","pages":"83-92"},"PeriodicalIF":0.0,"publicationDate":"2018-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S165943","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36754345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Secukinumab in the treatment of psoriasis: patient selection and perspectives. Secukinumab治疗牛皮癣:患者选择和观点。
Q1 DERMATOLOGY Pub Date : 2018-10-17 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S146004
Eric J Yang, Kristen M Beck, Wilson Liao

Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients. Important considerations in biologic selection include clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid disease. This article aims to outline the key considerations in patient selection for the treatment of plaque psoriasis with secukinumab.

Secukinumab是一种靶向IL-17A的人单克隆抗体,已被批准用于三种适应症:中度至重度斑块性银屑病、银屑病关节炎和强直性脊柱炎。在这三种适应症的III期临床试验中,secukinumab已被证明既高效又耐受性良好。然而,目前有几种生物药物被批准用于治疗中重度斑块性银屑病,并且许多药物显示出出色的疗效和安全性。由于这种广泛的选择,通常不清楚如何为特定患者选择生物制剂。生物制剂选择的重要考虑因素包括临床疗效、安全性、成本、便利性、起效和合并症的管理。本文旨在概述用secukinumab治疗斑块型银屑病患者选择时的关键考虑因素。
{"title":"Secukinumab in the treatment of psoriasis: patient selection and perspectives.","authors":"Eric J Yang,&nbsp;Kristen M Beck,&nbsp;Wilson Liao","doi":"10.2147/PTT.S146004","DOIUrl":"https://doi.org/10.2147/PTT.S146004","url":null,"abstract":"<p><p>Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients. Important considerations in biologic selection include clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid disease. This article aims to outline the key considerations in patient selection for the treatment of plaque psoriasis with secukinumab.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"8 ","pages":"75-82"},"PeriodicalIF":0.0,"publicationDate":"2018-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S146004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36675051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. 医师整体评估和体表面积组合工具是银屑病面积和严重程度指数评估银屑病的简单替代方案:来自原始和PRESTA的事后分析。
Q1 DERMATOLOGY Pub Date : 2018-10-08 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S169333
Jessica A Walsh, Heather Jones, Lotus Mallbris, Kristina Callis Duffin, Gerald G Krueger, Daniel O Clegg, Annette Szumski

Background: The product of Physician Global Assessment and Body Surface Area (PGA × BSA) is a new outcome measure for psoriasis severity and response to therapy. The objective of this study was to evaluate PGA × BSA as an alternative to Psoriasis Area and Severity Index (PASI) for psoriasis assessments.

Methods: The relationship between PASI and PGA × BSA was assessed in a post hoc analysis of pooled data from the PRISTINE (NCT00663052) and PRESTA (NCT00245960) trials in patients with moderate-to-severe psoriasis who received etanercept 50 mg/week. Data were analyzed using Spearman and intra-class correlation coefficients, effect sizes, scatterplots, Bland-Altman plots, and Kappa statistics.

Results: Spearman correlations at baseline, week 12, and week 24 were strong for PGA × BSA versus PASI (r=0.78, 0.87, and 0.90, respectively; all P<0.0001) as were intra-class correlations (0.76 [95% confidence interval 0.73-0.80], 0.80 [0.76-0.83], and 0.85 [0.82-0.87], respectively). The effect size was -1.53 for PASI and -0.94 for PGA × BSA (baseline to week 24). Scatterplots and Bland-Altman plots detected a trend across the range of measurement. Kappa statistics (at 12 and 24 weeks) between PASI50/75/90 and 50/75/90% improvement in PGA × BSA showed good agreement (0.58-0.69 at week 12 and 0.63-0.67, respectively; all P<0.0001). At baseline, the Spearman correlation coefficients were 0.96, 0.51, 0.19, and 0.17 for PGA × BSA versus BSA, PGA, Patient Global Assessment, and Dermatology Life Quality Index, respectively (all P<0.001).

Conclusion: PGA × BSA has advantages over PASI for measuring moderate-to-severe psoriasis; it is intuitive, sensitive, and easy to use.

背景:医师整体评估和体表面积(PGA × BSA)的产物是衡量银屑病严重程度和治疗反应的新指标。本研究的目的是评估PGA × BSA作为银屑病面积和严重程度指数(PASI)评估银屑病的替代方法。方法:PASI和PGA × BSA之间的关系通过对来自接受依那昔50 mg/周的中重度银屑病患者的朴素(NCT00663052)和PRESTA (NCT00245960)试验的汇总数据进行事后分析来评估。数据分析采用Spearman和类内相关系数、效应量、散点图、Bland-Altman图和Kappa统计。结果:基线、第12周和第24周,PGA × BSA与PASI的Spearman相关性很强(r分别=0.78、0.87和0.90;结论:PGA × BSA检测中重度牛皮癣优于PASI;它直观,灵敏,易于使用。
{"title":"The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA.","authors":"Jessica A Walsh,&nbsp;Heather Jones,&nbsp;Lotus Mallbris,&nbsp;Kristina Callis Duffin,&nbsp;Gerald G Krueger,&nbsp;Daniel O Clegg,&nbsp;Annette Szumski","doi":"10.2147/PTT.S169333","DOIUrl":"https://doi.org/10.2147/PTT.S169333","url":null,"abstract":"<p><strong>Background: </strong>The product of Physician Global Assessment and Body Surface Area (PGA × BSA) is a new outcome measure for psoriasis severity and response to therapy. The objective of this study was to evaluate PGA × BSA as an alternative to Psoriasis Area and Severity Index (PASI) for psoriasis assessments.</p><p><strong>Methods: </strong>The relationship between PASI and PGA × BSA was assessed in a post hoc analysis of pooled data from the PRISTINE (NCT00663052) and PRESTA (NCT00245960) trials in patients with moderate-to-severe psoriasis who received etanercept 50 mg/week. Data were analyzed using Spearman and intra-class correlation coefficients, effect sizes, scatterplots, Bland-Altman plots, and Kappa statistics.</p><p><strong>Results: </strong>Spearman correlations at baseline, week 12, and week 24 were strong for PGA × BSA versus PASI (<i>r</i>=0.78, 0.87, and 0.90, respectively; all <i>P</i><0.0001) as were intra-class correlations (0.76 [95% confidence interval 0.73-0.80], 0.80 [0.76-0.83], and 0.85 [0.82-0.87], respectively). The effect size was -1.53 for PASI and -0.94 for PGA × BSA (baseline to week 24). Scatterplots and Bland-Altman plots detected a trend across the range of measurement. Kappa statistics (at 12 and 24 weeks) between PASI50/75/90 and 50/75/90% improvement in PGA × BSA showed good agreement (0.58-0.69 at week 12 and 0.63-0.67, respectively; all <i>P</i><0.0001). At baseline, the Spearman correlation coefficients were 0.96, 0.51, 0.19, and 0.17 for PGA × BSA versus BSA, PGA, Patient Global Assessment, and Dermatology Life Quality Index, respectively (all <i>P</i><0.001).</p><p><strong>Conclusion: </strong>PGA × BSA has advantages over PASI for measuring moderate-to-severe psoriasis; it is intuitive, sensitive, and easy to use.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"8 ","pages":"65-74"},"PeriodicalIF":0.0,"publicationDate":"2018-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S169333","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36588165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients. 评估作为银屑病患者疾病严重程度潜在标志的 ADA 活性。
Q1 DERMATOLOGY Pub Date : 2018-09-04 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S174119
Seraj Ahmed Khan, Sudha Agrawal, Nirmal Baral, Madhab Lamsal

Background: Psoriasis is a dermatological disorder with a multifactorial origin and is associated with many biochemical and immunological changes.

Purpose: This study aimed to examine the association of serum ADA activity, uric acid (UA), and high-sensitivity CRP (hs-CRP) with psoriasis and the role of ADA in disease severity.

Materials and methods: In this comparative cross-sectional study, 50 clinically and histopathologically diagnosed psoriasis patients and 50 age- and sex-matched healthy controls were enrolled. Blood samples were taken and analysis of the biochemical parameters was performed according to Giuisti and Galanti method, uricase and ELISA technique for ADA activity, UA, and hs-CRP, respectively. The severity of the disease was scored according to Psoriasis Area and Severity Index (PASI). Statistical analysis of differences within and between the study groups was carried out using the Student's t-test, one-way post hoc ANOVA, and Pearson's correlation. Linear regression was used to establish the independent association of ADA with disease severity.

Results: The serum ADA activity, UA, and hs-CRP levels of the psoriatic patients were found to be significantly higher (P<0.001). hs-CRP was positively correlated with ADA and UA in patients (P<0.001). There was no significant difference in total cholesterol, low-density lipoprotein, and triacylglycerol in psoriasis patients, whereas we noted a decreased high-density lipoprotein level in psoriasis patients as compared to controls. Linear regression showed that ADA was independently associated with the disease severity and was statistically significant (P<0.001).

Conclusion: ADA activity was positively and significantly associated with the severity of psoriasis, therefore, it could be suggested as a marker for disease severity in psoriasis patients.

背景:目的:本研究旨在探讨血清 ADA 活性、尿酸(UA)和高敏 CRP(hs-CRP)与银屑病的关系,以及 ADA 在疾病严重程度中的作用:在这项横断面比较研究中,共纳入了 50 名经临床和组织病理学诊断的银屑病患者和 50 名年龄和性别匹配的健康对照者。采集血液样本,并根据 Giuisti 和 Galanti 法、尿酸酶和 ELISA 技术分别对 ADA 活性、UA 和 hs-CRP 进行生化指标分析。疾病的严重程度根据银屑病面积和严重程度指数(PASI)进行评分。采用学生 t 检验、单因素方差分析和皮尔逊相关分析对研究组内和研究组间的差异进行统计分析。线性回归用于确定 ADA 与疾病严重程度的独立关联:结果:发现银屑病患者的血清 ADA 活性、UA 和 hs-CRP 水平显著较高(PPP 结论:ADA 活性与银屑病严重程度呈显著正相关:ADA活性与银屑病的严重程度呈显著正相关,因此可作为银屑病患者疾病严重程度的标志物。
{"title":"Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients.","authors":"Seraj Ahmed Khan, Sudha Agrawal, Nirmal Baral, Madhab Lamsal","doi":"10.2147/PTT.S174119","DOIUrl":"10.2147/PTT.S174119","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a dermatological disorder with a multifactorial origin and is associated with many biochemical and immunological changes.</p><p><strong>Purpose: </strong>This study aimed to examine the association of serum ADA activity, uric acid (UA), and high-sensitivity CRP (hs-CRP) with psoriasis and the role of ADA in disease severity.</p><p><strong>Materials and methods: </strong>In this comparative cross-sectional study, 50 clinically and histopathologically diagnosed psoriasis patients and 50 age- and sex-matched healthy controls were enrolled. Blood samples were taken and analysis of the biochemical parameters was performed according to Giuisti and Galanti method, uricase and ELISA technique for ADA activity, UA, and hs-CRP, respectively. The severity of the disease was scored according to Psoriasis Area and Severity Index (PASI). Statistical analysis of differences within and between the study groups was carried out using the Student's <i>t</i>-test, one-way post hoc ANOVA, and Pearson's correlation. Linear regression was used to establish the independent association of ADA with disease severity.</p><p><strong>Results: </strong>The serum ADA activity, UA, and hs-CRP levels of the psoriatic patients were found to be significantly higher (<i>P</i><0.001). hs-CRP was positively correlated with ADA and UA in patients (<i>P</i><0.001). There was no significant difference in total cholesterol, low-density lipoprotein, and triacylglycerol in psoriasis patients, whereas we noted a decreased high-density lipoprotein level in psoriasis patients as compared to controls. Linear regression showed that ADA was independently associated with the disease severity and was statistically significant (<i>P</i><0.001).</p><p><strong>Conclusion: </strong>ADA activity was positively and significantly associated with the severity of psoriasis, therefore, it could be suggested as a marker for disease severity in psoriasis patients.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"8 ","pages":"59-63"},"PeriodicalIF":0.0,"publicationDate":"2018-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/88/ptt-8-059.PMC6130266.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36505191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. tildrakizumab-asmn治疗中重度斑块型银屑病的概况:迄今为止的证据。
Q1 DERMATOLOGY Pub Date : 2018-08-29 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S146640
Kristen M Beck, Isabelle M Sanchez, Eric J Yang, Wilson Liao

Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic therapies for this condition. Currently, biologic medications approved for the treatment of plaque psoriasis include tumor necrosis factor α inhibitors, interleukin (IL)-17 or IL-17 receptor inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors. Tildrakizumab-asmn is a monoclonal antibody that targets the p19 subunit of IL-23 and is approved for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This article reviews the current pharmacologic, efficacy, and safety data on tildrakizumab-asmn.

斑块型牛皮癣是一种免疫介导的皮肤病,在美国大约有3%的成年人患有此病。在过去的20年里,对银屑病免疫介导的病理生理学的研究取得了进展,这导致了针对银屑病的靶向生物疗法的发展。目前,被批准用于治疗斑块型银屑病的生物药物包括肿瘤坏死因子α抑制剂、白细胞介素(IL)-17或IL-17受体抑制剂、IL-12/23抑制剂和IL-23抑制剂。Tildrakizumab-asmn是一种靶向IL-23 p19亚基的单克隆抗体,已被批准用于中度至重度斑块性银屑病的成人患者,这些患者是全身治疗或光疗的候选人。本文综述了目前tildrakizumab-asmn的药理学、疗效和安全性数据。
{"title":"Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date.","authors":"Kristen M Beck,&nbsp;Isabelle M Sanchez,&nbsp;Eric J Yang,&nbsp;Wilson Liao","doi":"10.2147/PTT.S146640","DOIUrl":"https://doi.org/10.2147/PTT.S146640","url":null,"abstract":"<p><p>Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic therapies for this condition. Currently, biologic medications approved for the treatment of plaque psoriasis include tumor necrosis factor α inhibitors, interleukin (IL)-17 or IL-17 receptor inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors. Tildrakizumab-asmn is a monoclonal antibody that targets the p19 subunit of IL-23 and is approved for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This article reviews the current pharmacologic, efficacy, and safety data on tildrakizumab-asmn.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"8 ","pages":"49-58"},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S146640","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36491996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
期刊
Psoriasis (Auckland, N.Z.)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1